Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc." is generating significant coverage in the Business category, with 13 articles from 13 distinct sources tracked by PULSE so far.
Outlets currently covering the story include BioPharma Dive, FirstWord Pharma, qz.com and Reuters. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 133d ago.
Quick answers
Why is "Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc." trending?
Because 13 independent news sources published 13 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (13)
- Biogen adds more immune drugs in $1B buyout of secretive startup RayThera BioPharma Dive · 136d ago
- Biogen snaps up RayThera in $1B immunology deal FirstWord Pharma · 136d ago
- Biogen acquires RayThera in deal worth up to $1 billion qz.com · 136d ago
- Biogen targets immunology growth with $1 billion RayThera deal Reuters · 136d ago
- Biogen Inc. entered into a definitive agreement to acquire RayThera, Inc. from Foresite Capital Management, LLC, OrbiMed Advisors LLC, TTM Capital and others for $1 billion. marketscreener.com · 136d ago
- Needham reiterates Buy on Biogen stock after RayThera acquisition Investing.com · 136d ago
- Needham reiterates Buy on Biogen stock after RayThera acquisition By Investing.com Investing.com Canada · 136d ago
- Biogen inks $1B RayThera buyout to bag preclinical immunology assets Fierce Biotech · 136d ago
- BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal Stocktwits · 136d ago
- Biogen Expects to Close Deal in 3Q Moomoo · 136d ago
- Biogen (BIIB) to Acquire RayThera Inc. for Up to $1 Billion GuruFocus · 136d ago
- Biogen makes up to $1B deal for secretive anti-inflammatory biotech Endpoints News · 136d ago
- Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. Biogen · 136d ago
Topics
Related trends
AbbVie Revenue Rises on Strength in Immunology, Neuroscience
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Rare and common genetic variants shape single-cell immune gene expression
New studies show rare and common DNA variants jointly steer immune cell activity, tightening the link between genetics and disease.
US Business Activity Expands, Prices Surge by Most Since 2022
US business activity remains near five-year highs as pricing pressures surge to their most significant levels since August 2022.
Warning signs could predict inflammatory bowel disease a decade before diagnosis
Medical reports reveal that specific antibody signatures could predict inflammatory bowel disease a decade prior to formal diagnosis.
"Mind-blowing" Alzheimer’s breakthrough: Two hours of sleep restored without clearing brain plaques
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.